Translate Bio, a clinical-stage messenger RNA therapeutics company developing a new class of potentially transformative medicines to treat or prevent debilitating or life-threatening diseases, reported that on September 8, 2021, the Company granted restricted stock units for an aggregate of 54,078 shares of the Company’s common stock to twenty new employees.
September 8, 2021
· 2 min read